首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL7 |
| Uniprot No | P02775 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-128aa |
| 氨基酸序列 | MSSTKGQTKR NLAKGKEESL DSDLYAELRC MCIKTTSGIH PKNIQSLEVI GKGTHCNQVE VIATLKDGRK ICLDPDAPRI KKIVQKKLAG DESAD |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL7重组蛋白的3篇参考文献示例(注：文献信息为模拟内容，仅供参考)：
---
1. **文献名称**：*Recombinant CXCL7 Enhances Platelet Activation and Thrombus Formation via PAR4 Signaling*
**作者**：Smith A, et al.
**摘要**：该研究证实重组CXCL7通过激活血小板表面的PAR4受体，显著促进血小板聚集和血栓形成，揭示了其在病理性凝血中的潜在作用机制。
2. **文献名称**：*CXCL7 Promotes Angiogenesis in Chronic Wounds through VEGF Synergy*
**作者**：Zhang L, et al.
**摘要**：通过动物模型发现，重组CXCL7蛋白能够与血管内皮生长因子(VEGF)协同作用，刺激血管新生，加速慢性伤口的愈合过程。
3. **文献名称**：*Structural and Functional Characterization of Recombinant Human CXCL7*
**作者**：Johnson R, et al.
**摘要**：利用X射线晶体学解析了重组人CXCL7的三维结构，并证明其与硫酸乙酰肝素的结合对其趋化中性粒细胞的功能至关重要。
---
如需真实文献，建议在PubMed或Web of Science中检索关键词“CXCL7 recombinant protein”获取最新研究。
CXCL7. also known as neutrophil-activating peptide 2 (NAP-2) or platelet basic protein (PBP), is a member of the CXC chemokine family. It is primarily produced by platelets and megakaryocytes, stored in platelet α-granules, and released upon activation during vascular injury or inflammation. The protein exists in multiple processed forms, including platelet-derived growth factor (PDGF)-binding protein (PBP), connective tissue-activating peptide III (CTAP-III), β-thromboglobulin (β-TG), and the mature NAP-2. generated through proteolytic cleavage.
As a chemotactic factor, CXCL7 interacts with the CXCR2 receptor to recruit and activate neutrophils, promoting inflammatory responses and wound healing. It also exhibits angiogenic properties and participates in thrombus stabilization by binding to extracellular matrix components. Dysregulation of CXCL7 has been implicated in pathological conditions such as atherosclerosis, thrombosis, and cancer metastasis.
Recombinant CXCL7 protein is typically produced using Escherichia coli or mammalian expression systems, ensuring proper folding and post-translational modifications. The purified protein maintains biological activity for use in functional studies, including leukocyte migration assays, receptor-ligand interaction analyses, and signaling pathway investigations. Quality control involves SDS-PAGE, Western blotting, and endotoxin level verification. Researchers utilize recombinant CXCL7 to explore its role in inflammatory diseases, vascular biology, and tumor microenvironments, while pharmaceutical applications focus on developing therapeutic strategies targeting CXCL7-CXCR2 axis in inflammatory disorders or cancer immunotherapy.
×
